4/4
08:11 pm
supn
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
Neutral
Report
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
4/1
11:03 pm
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
3/24
11:06 pm
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
3/16
02:05 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
3/14
06:06 am
supn
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks [Yahoo! Finance]
Low
Report
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks [Yahoo! Finance]
3/13
10:27 am
supn
3 Small-Cap Stocks Skating on Thin Ice [Yahoo! Finance]
Low
Report
3 Small-Cap Stocks Skating on Thin Ice [Yahoo! Finance]
3/8
02:05 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
3/4
04:30 pm
supn
Supernus to Participate in Two Upcoming Investor Conferences
Low
Report
Supernus to Participate in Two Upcoming Investor Conferences
3/3
08:57 am
supn
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? [Yahoo! Finance]
Low
Report
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? [Yahoo! Finance]
2/27
10:03 pm
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
2/27
08:30 am
supn
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
Medium
Report
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
2/26
08:58 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $36.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $36.00 price target on the stock.
2/25
07:46 pm
supn
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
2/25
07:07 pm
supn
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/25
05:40 pm
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers [Yahoo! Finance]
2/25
04:01 pm
supn
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
2/24
09:02 am
supn
What To Expect From Supernus Pharmaceuticals's (SUPN) Q4 Earnings [Yahoo! Finance]
Medium
Report
What To Expect From Supernus Pharmaceuticals's (SUPN) Q4 Earnings [Yahoo! Finance]
2/19
11:33 am
supn
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation
Low
Report
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation
2/19
07:06 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock, down previously from $57.00.
Medium
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. They now have a $36.00 price target on the stock, down previously from $57.00.
2/18
04:25 pm
supn
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Medium
Report
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
2/11
06:29 pm
supn
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/11
04:30 pm
supn
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
2/4
09:51 am
supn
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease [Yahoo! Finance]
Low
Report
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease [Yahoo! Finance]
2/4
09:00 am
supn
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
Medium
Report
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
1/27
08:00 am
supn
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
Low
Report
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women